Search

Search Constraints

You searched for: Author/Creator Shustov, Andrei R.

Search Results

1. A phase I study of pulse high‐dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma. (29th January 2013)

2. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T‐cell lymphoma (PTCL): final results from the T‐ cell consortium trial. (2nd December 2015)

3. A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). (February 2016)

4. A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). (February 2016)

5. A pilot study of weekly brentuximab vedotin in patients with CD30+ malignancies resistant to brentuximab vedotin every 3 weeks. (28th December 2018)

6. A prospective cohort study of patients with peripheral T‐cell lymphoma in the United States. Issue 7 (2nd December 2016)

7. Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Issue 3 (March 2015)

8. Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity. Issue 1 (January 2015)

9. Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. (14th September 2018)

10. Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. Issue 7 (3rd July 2017)